Neuralink enabling people with ALS to speak again.

Neuralink has achieved a landmark clinical milestone with its first human patient, who is living with ALS. The individual received the company's N1 implant, a coin-sized device with over 1,000 electrodes that is surgically placed in the brain's motor cortex. Initial results show the patient can successfully control a computer cursor and engage in basic communication by thinking about moving a cursor to select letters on a screen. This represents a direct brain-to-digital interface restoring a function severely impaired by the neurodegenerative condition.

While Neuralink's long-term ambitions include treating a range of neurological conditions, this initial 'Telepathy' application focuses on restoring communication for people with quadriplegia. The technology works by decoding intended movement signals from the brain, bypassing damaged neural pathways. This proof-of-concept is a critical step toward FDA approval for broader use and demonstrates the potential for brain-computer interfaces (BCIs) to materially improve quality of life. The development places Neuralink in a growing field alongside companies like Synchron and Precision Neuroscience, all racing to make BCIs a practical medical reality.